Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 25, Issue 10, 2006, Pages 633-641

  Yakovlev, S V ^a   Stratchounski, L S ^b   Woods, G L ^c   Adeyi, B ^c   McCarroll, K A ^c   Ginanni, J A ^c   Friedland, I R ^c   Wood, C A ^c   DiNubile, M J ^c  

^a Municipal Hospital #7   (Russian Federation)

^b SMOLENSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CIPROFLOXACIN; ERTAPENEM; METRONIDAZOLE;

APACHE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; ENTEROBACTERIACEAE; HEALTH CARE FACILITY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MICROBIAL IDENTIFICATION; NURSING HOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STATISTICAL ANALYSIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEPHALOSPORINS; CROSS INFECTION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; SKILLED NURSING FACILITIES;

EID: 33749526100     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-006-0193-0     Document Type: Article

References (47)

1. Gross PA, van Antwerpen C (1983) Nosocomial infections and hospital deaths. A case-control study. Am J Med 75:658-662
2. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C (1999) The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 159:1249-1256
3. Tablan OC, Anderson LJ, Arden NH, Breiman RF, Butler JC, McNeil MM (1994) Guideline for prevention of nosocomial pneumonia. The Hospital Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Infect Control Hosp Epidemiol 15:587-627
4. Cook DJ, Kollef MH (1998) Risk factors for ICU-acquired pneumonia. JAMA 279:1605-1606
5. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C (1993) Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 94:281-288
6. Greenaway CA, Embil J, Orr PH, McLeod J, Dyck B, Nicolle LE (1997) Nosocomial pneumonia on general medical and surgical wards in a tertiary-care hospital. Infect Control Hosp Epidemiol 18:749-756
7. Lentino JR (2001) Nosocomial pneumonia: more than just ventilator-associated. Curr Infect Dis Rep 3:266-273
8. Myny D, Depuydt P, Colardyn F, Blot S (2005) Ventilator-associated pneumonia in a tertiary care ICU: analysis of risk factors for acquisition and mortality. Acta Clin Belg 60:114-121
9. Yu VL, Singh N (2004) Excessive antimicrobial usage causes measurable harm to patients with suspected ventilator-associated pneumonia. Intensive Care Med 30:735-738
10. Boyce JM, Potter-Bynoe G, Dziobek L, Solomon SL (1991) Nosocomial pneumonia in Medicare patients. Hospital costs and reimbursement patterns under the prospective payment system. Arch Intern Med 151:1109-1114
11. Craig CP, Connelly S (1984) Effect of intensive care unit nosocomial pneumonia on duration of stay and mortality. Am J Infect Control 12:233-238
12. Craven DE, Steger KA, Barber TW (1991) Preventing nosocomial pneumonia: state of the art and perspectives for the 1990s. Am J Med 91(Suppl 3B):44-53
13. Safdar N, Dezfulian C, Collard HR, Saint S (2005) Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 33:2184-2193
14. Carratala J, Neal S (2004) Health care-associated pneumonia: a new category of respiratory infection? Program and abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy. Abstract K-1236
15. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405-1433
16. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730-1754
17. Sopena N, Sabria M (2005) Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest 127:213-219
18. American Thoracic Society (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416
19. Craven DE, Palladino R, McQuillen DP (2004) Healthcare-associated pneumonia in adults: management principles to improve outcomes. Infect Dis Clin North Am 18:939-962
20. Chalfine A, Timsit JF, Acar J (2000) Antibiotic resistance in nosocomial pulmonary pathogens. Semin Respir Crit Care Med 21:45-51
21. Cross JT Jr, Campbell GD Jr (2001) Therapy of nosocomial pneumonia. Med Clin North Am 85:1583-1594
22. Lode H, Raffenberg M, Geerdes-Fenge H, Mauch H (2000) Monotherapy of nosocomial pneumonia. Semin Respir Crit Care Med 21:9-17
23. Fuchs PC, Barry AL, Brown SD (2001) In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 45:1915-1918
24. Livermore DM, Carter MW, Bagel S, Wiedemann B, Baquero F, Loza E, Endtz HP, van Den Braak N, Fernandes CJ, Fernandes L, Frimodt-Moller N, Rasmussen LS, Giamarellou H, Giamarellos-Bourboulis E, Jarlier V, Nguyen J, Nord CE, Struelens MJ, Nonhoff C, Turnidge J, Bell J, Zbinden R, Pfister S, Mixson L, Shungu DL (2001) In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 45:1860-1867
25. Livermore DM, Oakton KJ, Carter MW, Warner M (2001) Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. Antimicrob Agents Chemother 45:2831-2837
26. Shah PM, Isaacs RD (2003) Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 52:538-542
27. Zhanel GG, Johanson C, Embil JM, Noreddin A, Gin A, Vercaigne L, Hoban DJ (2005) Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther 3:23-39
28. Jacoby GA, Munoz-Price LS (2005) The new β-lactamases. N Engl J Med 352:380-391
29. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657-686
30. Gesser RM, McCarroll K, Teppler H, Woods GL (2003) Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. J Antimicrob Chemother 51:1253-1260
31. Teppler H, Gesser RM, Friedland IR, Woods GL, Meibohm A, Herman G, Mistry G, Isaacs R (2004) Safety and tolerability of ertapenem. J Antimicrob Chemother 53(Suppl 2):75-81
32. Vetter N, Cambronero-Hernandez E, Rohlf J, Simon S, Carides A, Oliveria T, Isaacs R (2002) A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 24:1770-1785
33. Woods GL, Isaacs RD, McCarroll KA, Friedland IR (2003) Ertapenem therapy for community-acquired pneumonia in the elderly. J Am Geriatr Soc 51:1526-1532
34. Beam Jr TR, Gilbert DN, Kunin CM (1992) General guidelines for the clinical evaluation of anti-infective drug products. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 15(Suppl 1):5-32
35. Miettinen O, Nurminen M (1985) Comparative analysis of two rates. Stat Med 4:213-226
36. Hoffken G, Niederman MS (2002) Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 122:2183-2196
37. Keith DD, Garrett KM, Hickox G, Echols B, Comeau E (2004) Ventilator-associated pneumonia: improved clinical outcomes. J Nurs Care Qual 19:328-333
38. Kollef MH (2005) What is ventilator-associated pneumonia and why is it important? Respir Care 50:714-721
39. Mehta RM, Niederman MS (2003) Nosocomial pneumonia in the intensive care unit: controversies and dilemmas. J Intensive Care Med 18:175-188
40. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 31:347-382
41. Ramphal R (2005) Importance of adequate initial antimicrobial therapy. Chemotherapy 51:171-176
42. Joshi M, Bernstein J, Solomkin J, Wester BA, Kuye O (1999) Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. J Antimicrob Chemother 43:389-397
43. Rubinstein E, Cammarata S, Oliphant T, Wunderink R (2001) Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 32:402-412
44. Kollef MH (2004) Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. Respir Care 49:1530-1541
45. Paramythiotou E, Lucet J-C, Timsit J-F, Vanjak D, Paugam-Burtz C, Trouillet J-L, Belloc S, Kassis N, Karabinis A, Andremont A (2004) Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 38:670-677
46. Apfalter P, Stoiser B, Barousch W, Nehr M, Kramer L, Burgmann H (2005) Community-acquired bacteria frequently detected by means of quantitative polymerase chain reaction in nosocomial early-onset ventilator-associated pneumonia. Crit Care Med 33:1492-1498
47. Hicks PS, Pelak B, Woods GL, Bartizal KF, Motyl M (2002) Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections. Clin Microbiol Infect 8:753-757